Patient Resources

What are clinical trials and who can participate?

Learn more

Seattle Genetics is focused on generating clinical data that support the utility of our innovative product candidates in improving the treatment and outcomes for patients with cancer. We post clinical trial protocol information for our studies on the National Institutes of Health (NIH) Clinical Trials website at www.clinicaltrials.gov.

For information on other trials sponsored by investigators, search clinicaltrials.gov

Moving from promise to practice in the clinic

Trials by Therapeutic Areas

Hodgkin Lymphoma

  • Phase 3 ECHELON-1 trial in patients with advanced classical Hodgkin lymphoma. Study #C25003 [learn more]
  • Phase 3 AETHERA trial in patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005 [learn more]
  • Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above. Study #SGN35-015 [learn more]
  • Phase 1/2 trial in patients with relapsed or refractory Hodgkin lymphoma. Study #SGN35-016 [learn more]
Learn more about Hodgkin lymphoma clinical trials

Non-Hodgkin Lymphoma

  • Phase 3 ALCANZA trial in patients with relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 [learn more]
  • Phase 3 ECHELON-2 trial in patients with newly diagnosed mature T-cell lymphomas. Study #SGN35-014 [learn more]
  • Phase 2 trial in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. Study #SGN35-012 [learn more]
  • Phase 2 study in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). Study #SGN35-017 [learn more]
  • Phase 1 trial in patients with B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia) and highly aggressive lymphomas. Study #SGN19A-001 [learn more]
  • Phase 1 trial in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-002 [learn more]
  • Phase 1 trial in patients with relapsed or refractory non-Hodgkin lymphoma. Study #SGN70A-001 [learn more]
Learn more about non-Hodgkin lymphoma clinical trials

Leukemia & Other Blood Cancers

  • Phase 2 study in patients with CD30-positive malignancies other than lymphoma, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and a number of solid tumors. Study #SGN35-013 [learn more]
  • Phase 1 trial in patients with B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia) and highly aggressive lymphomas. Study #SGN19A-0001 [learn more]
  • Phase 1 trial in patients with acute myeloid leukemia. Study #SGN33A-001 [learn more]
Learn more about leukemia and other blood cancer clinical trials

Solid Tumors

  • Phase 2 study in patients with CD30-positive malignancies other than lymphoma, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and a number of solid tumors. Study #SGN35-013 [learn more]
  • Phase 1 trial in patients with metastatic breast cancer. Study #SGNLVA-001 [learn more]
  • Phase 1 trial in patients with relapsed or refractory renal cell carcinoma. Study #SGN70A-001 [learn more]
  • Phase 1 trial in malignant solid tumors that express Nectin-4. Study #AGS-22M6E-11-1 [learn more]
  • Phase 1 trial in patients with bladder cancer. Study #AGS15E-13-1 [learn more]
Learn more about solid tumor clinical trials

Trials by Program

Brentuximab Vedotin

  • Phase 3 ECHELON-1 trial in newly diagnosed patients with advanced classical Hodgkin lymphoma. Study #C25003 [learn more]
  • Phase 3 ECHELON-2 trial in patients with newly diagnosed mature T-cell lymphomas. Study #SGN35-014 [learn more]
  • Phase 3 AETHERA trial in patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005 [learn more]
  • Phase 3 ALCANZA trial in patients with relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 [learn more]
  • Phase 2 trial in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. Study #SGN35-012 [learn more]
  • Phase 2 study in patients with CD30-positive malignancies other than lymphoma, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and a number of solid tumors. Study #SGN35-013 [learn more]
  • Phase 2 study for frontline treatment of diffuse large B-cell lymphoma (DLBCL). Study #SGN35-017 [learn more]
  • Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above. Study #SGN35-015 [learn more]
  • Phase 1/2 trial in patients with relapsed or refractory Hodgkin lymphoma. Study #SGN35-016 [learn more]

SGN-CD19A

  • Phase 1 trial in B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia) and highly aggressive lymphomas. Study #SGN19A-001 [learn more]
  • Phase 1 trial in relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-002 [learn more]

SGN-CD33A

  • Phase 1 trial in patients with acute myeloid leukemia. Study #SGN33A-001 [learn more]

SGN-LIV1A

  • Phase 1 trial in patients with metastatic breast cancer. Study #SGNLVA-001 [learn more]

SGN-CD70A

  • Phase 1 trial in patients with relapsed or refractory renal cell carcinoma or non-Hodgkin lymphoma. Study #SGN70A-001 [learn more]

ASG-22ME

  • Phase 1 trial in malignant solid tumors that express Nectin-4. Study #AGS-22M6E-11-1 [learn more]

ASG-15ME

  • Phase 1 trial in bladder cancer. Study #AGS15E-13-1 [learn more]

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com